Xuan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xuan Zhang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Meifang Yang
State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
5 shared publications- Lanjuan Li
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on Infection Research and Drug Development, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China
4 shared publications Hong Zhao
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China
3 shared publicationsHuihui Dong
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China
3 shared publicationsJianhua Hu
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China
3 shared publicationsDongsheng Han
Department of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications
Latest Publications
- 26 July 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (11) , 2623-2634
Clinical performance of metagenomic next-generation sequencing in the diagnosis of Epstein-Barr virus central nervous system infections
Metagenomic next-generation sequencing (mNGS) has been widely utilized for diagnosing infectious diseases. However, studies employing mNGS to detect EBV central nervous system (CNS) infections remain scarce. Therefore, this study aimed to evaluate the diagnostic performance of mNGS in EBV CNS infections. Patients discharged with the diagnosis of CNS viral infection and underwent lumbar puncture for mNGS of cerebrospinal fluid between January 2021 and May 2024 were selected. The selected cerebrospinal fluid samples were subjected to PCR, including those that were EBV-negative in mNGS. Clinical data were collected for analysis. A total of 96 samples were included: 18 samples in the EBV infection group (PCR EBV DNA +), 30 samples in the suspected EBV infection group (PCR EBV DNA - but mNGS +), and 48 samples in the non-EBV-infected group (PCR EBV DNA - and mNGS -). All PCR-positive samples were also positive by mNGS, and in the EBV infection group, the viral load detected by PCR was strongly correlated with the number of sequences identified by mNGS (ρ = 0.752, p = 0.00). The number of sequences in the EBV infection group was higher than that in the suspected EBV infection group (14 vs. 4, p = 0.04). Patients in the EBV high sequence group experienced fewer headaches, nausea, and vomiting, had less elevated intracranial pressure, but required longer hospitalization (p = 0.003, 0.005, 0.03, and 0.03, respectively). The mNGS method is a sensitive tool for detecting EBV CNS infections.
- 26 July 2025
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (11) , 2623-2634
Clinical performance of metagenomic next-generation sequencing in the diagnosis of Epstein-Barr virus central nervous system infections
Metagenomic next-generation sequencing (mNGS) has been widely utilized for diagnosing infectious diseases. However, studies employing mNGS to detect EBV central nervous system (CNS) infections remain scarce. Therefore, this study aimed to evaluate the diagnostic performance of mNGS in EBV CNS infections. Patients discharged with the diagnosis of CNS viral infection and underwent lumbar puncture for mNGS of cerebrospinal fluid between January 2021 and May 2024 were selected. The selected cerebrospinal fluid samples were subjected to PCR, including those that were EBV-negative in mNGS. Clinical data were collected for analysis. A total of 96 samples were included: 18 samples in the EBV infection group (PCR EBV DNA +), 30 samples in the suspected EBV infection group (PCR EBV DNA - but mNGS +), and 48 samples in the non-EBV-infected group (PCR EBV DNA - and mNGS -). All PCR-positive samples were also positive by mNGS, and in the EBV infection group, the viral load detected by PCR was strongly correlated with the number of sequences identified by mNGS (ρ = 0.752, p = 0.00). The number of sequences in the EBV infection group was higher than that in the suspected EBV infection group (14 vs. 4, p = 0.04). Patients in the EBV high sequence group experienced fewer headaches, nausea, and vomiting, had less elevated intracranial pressure, but required longer hospitalization (p = 0.003, 0.005, 0.03, and 0.03, respectively). The mNGS method is a sensitive tool for detecting EBV CNS infections.
- Open Access
- 1 October 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 4501-4510
Clinical Features and Prognosis of Patients with COVID-19 and B-Cell Non-Hodgkin Lymphoma
Purpose: There is a lack of real-world data on the epidemiology, clinical manifestations, treatment effects, and prognosis of coronavirus disease 2019 (COVID-19) in patients with B-cell non-Hodgkin lymphoma (B-NHL). This study aimed to investigate the clinical features and prognostic factors of COVID-19 in patients with B-NHL. Patients and Methods: This study included individuals diagnosed with B-NHL who were also diagnosed with COVID-19 and hospitalized. A retrospective analysis was conducted, and univariate and multivariate logistic regression were used to identify independent factors affecting the duration of the positive-to-negative transition of COVID-19 nucleic acid test results and prognoses. Receiver operating characteristic curves were used to assess diagnostic accuracy and determine the optimal threshold. Results: Among 80 patients with COVID-19 and B-NHL, relapsed or refractory lymphoma and diffuse large B-cell lymphoma (DLBCL) accounted for 13.8% and 65% of cases, respectively. The mean age was 60.4 ± 13.0 years, and 50% of patients were women. The median duration of the positive-to-negative transition was 14 days (interquartile range [IQR], 17.2), and the median hospitalization duration was 12 days (IQR, 13). The rate of severe disease was 26.25%, and the 28-day mortality rate was 10.00%. Univariate and multivariate logistic regression analyses revealed that pathological classification of B-NHL, infection with COVID-19 within 3 months after the last dose of anti-CD20 monoclonal antibodies, and corticosteroid use were independent factors associated with a prolonged duration of the positive-to-negative transition. Compared with patients with DLBCL or FL and COVID-19, patients with B-NHL had longer nucleic acid test transition durations and higher rates of severe disease and mortality. Conclusion: In patients with B-NHL, infection with COVID-19 within 3 months after treatment with anti-CD20 monoclonal antibodies prolonged the positive-to-negative transition of nucleic acid test results and increased the risks of severe disease and 28-day mortality. Treatment with corticosteroids further prolonged this transition.
- 1 October 2024
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 4501-4510
Open AccessClinical Features and Prognosis of Patients with COVID-19 and B-Cell Non-Hodgkin Lymphoma
Purpose: There is a lack of real-world data on the epidemiology, clinical manifestations, treatment effects, and prognosis of coronavirus disease 2019 (COVID-19) in patients with B-cell non-Hodgkin lymphoma (B-NHL). This study aimed to investigate the clinical features and prognostic factors of COVID-19 in patients with B-NHL. Patients and Methods: This study included individuals diagnosed with B-NHL who were also diagnosed with COVID-19 and hospitalized. A retrospective analysis was conducted, and univariate and multivariate logistic regression were used to identify independent factors affecting the duration of the positive-to-negative transition of COVID-19 nucleic acid test results and prognoses. Receiver operating characteristic curves were used to assess diagnostic accuracy and determine the optimal threshold. Results: Among 80 patients with COVID-19 and B-NHL, relapsed or refractory lymphoma and diffuse large B-cell lymphoma (DLBCL) accounted for 13.8% and 65% of cases, respectively. The mean age was 60.4 ± 13.0 years, and 50% of patients were women. The median duration of the positive-to-negative transition was 14 days (interquartile range [IQR], 17.2), and the median hospitalization duration was 12 days (IQR, 13). The rate of severe disease was 26.25%, and the 28-day mortality rate was 10.00%. Univariate and multivariate logistic regression analyses revealed that pathological classification of B-NHL, infection with COVID-19 within 3 months after the last dose of anti-CD20 monoclonal antibodies, and corticosteroid use were independent factors associated with a prolonged duration of the positive-to-negative transition. Compared with patients with DLBCL or FL and COVID-19, patients with B-NHL had longer nucleic acid test transition durations and higher rates of severe disease and mortality. Conclusion: In patients with B-NHL, infection with COVID-19 within 3 months after treatment with anti-CD20 monoclonal antibodies prolonged the positive-to-negative transition of nucleic acid test results and increased the risks of severe disease and 28-day mortality. Treatment with corticosteroids further prolonged this transition.
- 7 August 2024
- Published by Taylor & Francis in Future Microbiology
- Vol. 19 (13) , 1111-1117
Meta-genomic next-generation sequencing in the diagnosis of brucellosis: Five cases from a non-endemic area
- 7 August 2024
- Published by Taylor & Francis in Future Microbiology
- Vol. 19 (13) , 1111-1117
Meta-genomic next-generation sequencing in the diagnosis of brucellosis: Five cases from a non-endemic area
- Open Access
- 7 March 2017
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 45 (2) , 762-770
Incidence, risk factors and the effect of polyomavirus infection in hematopoietic stem cell transplant recipients
Objective: The effect of polyomavirus infection in HSCT recipients is poorly understood. Methods: We evaluated 38 HSCT recipients. Polyomavirus was detected by nested qualitative polymerase chain reaction (PCR) assays of urine. The risk factors for BK virus and JC virus were analysed. The kidney and liver functions of infected and uninfected patients were compared. Results: BK virus, JC virus, and simian virus 40 were detected in 21%, 42%, and 0% of HSCT recipients respectively. HCMV infection was found to be an independent risk factor for JC virus infection (odds ratio (OR): 8.528), while transplants with mismatched HLA are more susceptible to BK virus infection (OR: 12.000). Liver function of JC virus-infected subjects was worse than that of uninfected subjects. Conclusion: We must be vigilant for opportunistic polyomavirus infections in HSCT recipients, especially those with HCMV co-infection or a mismatched HLA transplant. When unexplained liver function deterioration is observed, JC virus infection should be considered.
- 7 March 2017
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 45 (2) , 762-770
Open AccessIncidence, risk factors and the effect of polyomavirus infection in hematopoietic stem cell transplant recipients
Objective: The effect of polyomavirus infection in HSCT recipients is poorly understood. Methods: We evaluated 38 HSCT recipients. Polyomavirus was detected by nested qualitative polymerase chain reaction (PCR) assays of urine. The risk factors for BK virus and JC virus were analysed. The kidney and liver functions of infected and uninfected patients were compared. Results: BK virus, JC virus, and simian virus 40 were detected in 21%, 42%, and 0% of HSCT recipients respectively. HCMV infection was found to be an independent risk factor for JC virus infection (odds ratio (OR): 8.528), while transplants with mismatched HLA are more susceptible to BK virus infection (OR: 12.000). Liver function of JC virus-infected subjects was worse than that of uninfected subjects. Conclusion: We must be vigilant for opportunistic polyomavirus infections in HSCT recipients, especially those with HCMV co-infection or a mismatched HLA transplant. When unexplained liver function deterioration is observed, JC virus infection should be considered.
- Open Access
- 1 January 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-3
Relationship between Malaria and ABO Blood Types in East China
Objectives. This study aims at investigating the relationship between malaria and blood group types in east China. Methods. Between 1 January 2011 and 31 March 2017, 99 malaria patients were enrolled for the study. Laboratory tests were conducted on their infection status and blood types. Clinical data of the participants were retrieved for analysis. Results. There was no mortality during the period of study. Overall, 90 (90.91%) of the patients were positive for Plasmodium falciparum, 8 (8.08%) were infected with Plasmodium vivax, and only 1 (1.01%) was infected with Plasmodium malariae. The most common blood group among the participants was group O (38.38%) followed by blood groups A, B, and AB, with 32.32%, 22.22%, and 7.07% cases, respectively. There was no significant relationship between the prevalence of malaria and ABO blood types (). In the blood group O, the prevalence of haemolytic-uremic syndrome and cerebral malaria was 13.16% and 5.25%, respectively, which was lower than that of the other three blood types (). Conclusion. There was no mortality among the malaria patients in this study. The blood group O was the most common blood type. Due to small sample size of data, there was no significant association between ABO blood types and malaria infection.- 1 January 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-3
Open AccessRelationship between Malaria and ABO Blood Types in East China
Objectives. This study aims at investigating the relationship between malaria and blood group types in east China. Methods. Between 1 January 2011 and 31 March 2017, 99 malaria patients were enrolled for the study. Laboratory tests were conducted on their infection status and blood types. Clinical data of the participants were retrieved for analysis. Results. There was no mortality during the period of study. Overall, 90 (90.91%) of the patients were positive for Plasmodium falciparum, 8 (8.08%) were infected with Plasmodium vivax, and only 1 (1.01%) was infected with Plasmodium malariae. The most common blood group among the participants was group O (38.38%) followed by blood groups A, B, and AB, with 32.32%, 22.22%, and 7.07% cases, respectively. There was no significant relationship between the prevalence of malaria and ABO blood types (). In the blood group O, the prevalence of haemolytic-uremic syndrome and cerebral malaria was 13.16% and 5.25%, respectively, which was lower than that of the other three blood types (). Conclusion. There was no mortality among the malaria patients in this study. The blood group O was the most common blood type. Due to small sample size of data, there was no significant association between ABO blood types and malaria infection. - Open Access
- 1 August 2016
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (35) , e4482
Occurrence of infective endocarditis following endoscopic variceal ligation therapy
Endoscopic variceal ligation (EVL) is the endoscopic treatment of acute esophageal variceal hemorrhage, however, prophylaxis antibiotic during EVL is controversial. We reported a 60-year-old man with diabetes, liver cirrhosis and hepatocellular carcinoma who received EVL for esophageal variceal haemorrhage. On the second day after EVL, the patient developed fever and chills. A week after EVL, the blood cultures were viridans streptococcus positive, and echocardiogram showed a vegetation on the cardiac valve. The patient was therefore diagnosed with infective endocarditis (IE). The patient was cured after 7 weeks of intravenous piperacillin sulbactam sodium. No complications were observed during the 3-month follow-up after discharge. To our knowledge, this is the first documented case to report IE caused by viridans streptococcus after EVL. Therefore, whether prophylaxis antibiotic should be administered to cirrhotic patients receiving EVL is worth further research.
- 1 August 2016
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (35) , e4482
Open AccessOccurrence of infective endocarditis following endoscopic variceal ligation therapy
Endoscopic variceal ligation (EVL) is the endoscopic treatment of acute esophageal variceal hemorrhage, however, prophylaxis antibiotic during EVL is controversial. We reported a 60-year-old man with diabetes, liver cirrhosis and hepatocellular carcinoma who received EVL for esophageal variceal haemorrhage. On the second day after EVL, the patient developed fever and chills. A week after EVL, the blood cultures were viridans streptococcus positive, and echocardiogram showed a vegetation on the cardiac valve. The patient was therefore diagnosed with infective endocarditis (IE). The patient was cured after 7 weeks of intravenous piperacillin sulbactam sodium. No complications were observed during the 3-month follow-up after discharge. To our knowledge, this is the first documented case to report IE caused by viridans streptococcus after EVL. Therefore, whether prophylaxis antibiotic should be administered to cirrhotic patients receiving EVL is worth further research.
- Open Access
- 14 May 2014
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 8 (1) , 25-30
Clinical findings of 40 patients with nocardiosis: A retrospective analysis in a tertiary hospital
To the best of our knowledge, no Chinese case studies concerning Nocardia infection have been published to date. Therefore, the present study aimed to retrospectively evaluate the risk factors, clinical features, imaging results, laboratory abnormalities, treatments and outcomes of nocardiosis in a Chinese tertiary hospital. Data collected from patients with laboratory-confirmed nocardiosis were retrospectively analyzed. A total of 40 patients who had a positive culture of Nocardia were included. The median time between the onset of symptoms and diagnosis was 42 days. Underlying diseases were identified in 72.5% of the patients of which diabetes was the most common (32.5%). The most important risk factor was corticosteroid administration. Fever and cough were common clinical symptoms. The pleuropulmonary (85%) were the most frequently involved sites and the disseminated disease rate was 30.0%. Frequent chest computed tomography scans revealed the presence of airspace opacities, nodules and masses, in addition to cavitary lesions that were particularly common among the study group. Brain images revealed lesions associated with abscesses. The majority of the patients (71.1%) were treated with trimethoprim sulfamethoxazole alone or in combination with other drugs. The in-hospital mortality rate was 15.0%. Disseminated disease, immunocompromised patients, an older age, brain involvement and concomitant infections were associated with a poor prognosis. Nocardiosis is an uncommon but emerging disease. The present study reports the first case series on nocardiosis from China and provides important information on the clinical features and risk factors of nocardiosis. Early recognition of the disease and the initiation of appropriate treatment are essential for a good prognosis.
- 14 May 2014
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 8 (1) , 25-30
Open AccessClinical findings of 40 patients with nocardiosis: A retrospective analysis in a tertiary hospital
To the best of our knowledge, no Chinese case studies concerning Nocardia infection have been published to date. Therefore, the present study aimed to retrospectively evaluate the risk factors, clinical features, imaging results, laboratory abnormalities, treatments and outcomes of nocardiosis in a Chinese tertiary hospital. Data collected from patients with laboratory-confirmed nocardiosis were retrospectively analyzed. A total of 40 patients who had a positive culture of Nocardia were included. The median time between the onset of symptoms and diagnosis was 42 days. Underlying diseases were identified in 72.5% of the patients of which diabetes was the most common (32.5%). The most important risk factor was corticosteroid administration. Fever and cough were common clinical symptoms. The pleuropulmonary (85%) were the most frequently involved sites and the disseminated disease rate was 30.0%. Frequent chest computed tomography scans revealed the presence of airspace opacities, nodules and masses, in addition to cavitary lesions that were particularly common among the study group. Brain images revealed lesions associated with abscesses. The majority of the patients (71.1%) were treated with trimethoprim sulfamethoxazole alone or in combination with other drugs. The in-hospital mortality rate was 15.0%. Disseminated disease, immunocompromised patients, an older age, brain involvement and concomitant infections were associated with a poor prognosis. Nocardiosis is an uncommon but emerging disease. The present study reports the first case series on nocardiosis from China and provides important information on the clinical features and risk factors of nocardiosis. Early recognition of the disease and the initiation of appropriate treatment are essential for a good prognosis.
- Open Access
- 10 December 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12) , e51224
Quantification of Cytomegalovirus Glycoprotein Bn DNA in Hematopoietic Stem Cell Transplant Recipients by Real-time PCR
Based on sequence variation in the N-terminus of the UL55 gene, which encodes glycoprotein B (gB), human cytomegalovirus (CMV) can be classified into four gBn genotypes. We assessed the distribution of CMV gBn genotypes and the correlation between CMV gBn DNA (detected by real-time PCR) and CMV-positive pp65 cells (identified by immunohistochemical staining) in a cohort of hematopoietic stem cell transplant patients. The distribution of gB genotypes was as follows: gBn1, 60% of patients; gBn2, 13.3%; mixed gBn1 and gBn3 infection, 26.7%; and gBn4 and other mixed infections, 0%. CMV gBn1 was the most common genotype. The detected level of CMV gB DNA correlated well with the number of CMV-positive pp65 cells detected by immunostaining (r = 0.585).
- 10 December 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12) , e51224
Open AccessQuantification of Cytomegalovirus Glycoprotein Bn DNA in Hematopoietic Stem Cell Transplant Recipients by Real-time PCR
Based on sequence variation in the N-terminus of the UL55 gene, which encodes glycoprotein B (gB), human cytomegalovirus (CMV) can be classified into four gBn genotypes. We assessed the distribution of CMV gBn genotypes and the correlation between CMV gBn DNA (detected by real-time PCR) and CMV-positive pp65 cells (identified by immunohistochemical staining) in a cohort of hematopoietic stem cell transplant patients. The distribution of gB genotypes was as follows: gBn1, 60% of patients; gBn2, 13.3%; mixed gBn1 and gBn3 infection, 26.7%; and gBn4 and other mixed infections, 0%. CMV gBn1 was the most common genotype. The detected level of CMV gB DNA correlated well with the number of CMV-positive pp65 cells detected by immunostaining (r = 0.585).
- Retracted
- 4 May 2009
- Published by Elsevier in Journal of Virological Methods
- Vol. 160 (1-2) , 74-77
RETRACTED: Monitoring of human cytomegalovirus glycoprotein B genotypes using real-time quantitative PCR in immunocompromised Chinese patients
- 4 May 2009
- Published by Elsevier in Journal of Virological Methods
- Vol. 160 (1-2) , 74-77
RetractedRETRACTED: Monitoring of human cytomegalovirus glycoprotein B genotypes using real-time quantitative PCR in immunocompromised Chinese patients
- Open Access
- 1 February 2009
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 37 (1) , 31-36
Monitoring of Human Cytomegalovirus Infection in Bone Marrow and Liver Transplant Recipients by Antigenaemia Assay and Enzyme-Linked Immunosorbent Assay
Human cytomegalovirus (HCMV) infection is a common complication in transplant recipients. Sensitive, specific and timely diagnostic tests for the detection of HCMV infection remain essential for successful therapy. The results of three tests to detect HCMV in bone marrow and liver transplant recipients were compared: a pp65 antigenaemia assay, an immediate-early (IE) antigenaemia assay and an anti-HCMV immunoglobulin M (IgM) antibody enzyme-linked immunosorbent assay (ELISA). Of 1344 samples, 911 (67.8%) and 917 (68.2%) samples were positive for pp65 and IE, respectively. The coincidence level was 85.1%. There was no statistical difference after transplantation to the first positive detection of HCMV (mean first checkout time) between the pp65 and IE antigenaemia assays. Moreover, the levels of HCMV detected by the pp65 and IE antigenaemia assays were significantly correlated. The HCMV-positivity rate as detected by the anti-HCMV IgM ELISA was 11.1%, which was significantly different from the IE and pp65 antigenaemia assays. We suggest that the IE antigenaemia assay could replace the pp65 antigenaemia assay for monitoring active HCMV infection and early detection of HCMV infection.
- 1 February 2009
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 37 (1) , 31-36
Open AccessMonitoring of Human Cytomegalovirus Infection in Bone Marrow and Liver Transplant Recipients by Antigenaemia Assay and Enzyme-Linked Immunosorbent Assay
Human cytomegalovirus (HCMV) infection is a common complication in transplant recipients. Sensitive, specific and timely diagnostic tests for the detection of HCMV infection remain essential for successful therapy. The results of three tests to detect HCMV in bone marrow and liver transplant recipients were compared: a pp65 antigenaemia assay, an immediate-early (IE) antigenaemia assay and an anti-HCMV immunoglobulin M (IgM) antibody enzyme-linked immunosorbent assay (ELISA). Of 1344 samples, 911 (67.8%) and 917 (68.2%) samples were positive for pp65 and IE, respectively. The coincidence level was 85.1%. There was no statistical difference after transplantation to the first positive detection of HCMV (mean first checkout time) between the pp65 and IE antigenaemia assays. Moreover, the levels of HCMV detected by the pp65 and IE antigenaemia assays were significantly correlated. The HCMV-positivity rate as detected by the anti-HCMV IgM ELISA was 11.1%, which was significantly different from the IE and pp65 antigenaemia assays. We suggest that the IE antigenaemia assay could replace the pp65 antigenaemia assay for monitoring active HCMV infection and early detection of HCMV infection.